Guangdong Hybribio Biotech Co.,Ltd.
SHZ: 300639.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jianyu Wang
- Employees
- 2,669
- Headquarters
- Chaozhou, Hong Kong SAR China
- IPO year
- 2017
- Market cap
- CN¥4.2B
- Website
- https://www.hybribio.cn
Loading 300639…
Loading profile data…Frequently asked questions about 300639
What does Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) do?
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offer...
Where does 300639.SZ trade?
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) trades on the Shenzhen Stock Exchange.
What sector is 300639.SZ in?
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Guangdong Hybribio Biotech Co.,Ltd.?
Jianyu Wang is the chief executive officer of Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ).
Where is Guangdong Hybribio Biotech Co.,Ltd. headquartered?
Guangdong Hybribio Biotech Co.,Ltd. is headquartered in Hong Kong SAR China.
Does 300639.SZ pay a dividend?
Yes — Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) paid a trailing twelve-month dividend of CNY 0.07 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 300639.SZ go public?
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) completed its initial public offering in 2017.